Reach Us +44-1235425476
Targeted use of Alpha Particles: Current Status in Cancer Therapeutics | OMICS International | Abstract
ISSN: 2155-9619

Journal of Nuclear Medicine & Radiation Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Targeted use of Alpha Particles: Current Status in Cancer Therapeutics

Oliver Sartor3,4,5*, Bassam N Maalouf3,4, Carlin R Hauck3 and Roger M Macklis1,2

1Department of Radiation Oncology, Cleveland Clinic Lerner College of Medicine, USA

2Taussig Cancer Center, Cleveland Clinic Lerner College of Medicine, USA

3ulane University School of Medicine, USA

4Department of Medicine, Section of Hematology-Oncology, USA

5Tulane cancer center, USA

*Corresponding Author:
Oliver Sartor
Laborde Professor of Cancer Research
Tulane Cancer Center
New Orleans, Louisiana, USA
Tel: +504 988 7869
Fax: +504 988 5059
E-mail: [email protected]

Received date: July 12, 2012; Accepted date: August 02, 2012; Published date: August 22, 2012

Citation: Sartor O, Maalouf BN, Hauck CR, Macklis RM (2012) Targeted use of Alpha Particles: Current Status in Cancer Therapeutics. J Nucl Med Radiat Ther 3:136. doi:10.4172/2155-9619.1000136

Copyright: © 2012 Sartor O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Purpose of review: To summarize the current role of alpha particles in cancer treatment including both clinical and pre-clinical data.

Recent findings: Though discovered more than hundred years ago, no targeted alpha emitters have yet to be approved as a systemic approach to cancer therapy. Until recently, most approaches to target alpha particle emitters utilized conjugation with antibodies through chelators. Limited clinical data are available using this approach; most alpha emitters have been studied in pre-clinical models though 213bismuth has been studied in leukemic patients. The novel alpha emitter 223radium has been studied more extensively than other agents in this class and a recent large randomized phase III trial data with 223radium demonstrates overall survival benefit in castrate resistant prostate cancer patients with skeletal metastasis.

Summary: The alpha emitter 223radium is expected to play a significant future role in therapy for bone-metastatic disease and a variety of novel alpha emitters offer the potential for targeted therapy via conjugation with specific antibodies or targeted nanoparticles.


Recommended Conferences

Clinical Oncology & Radiation Therapy

Singapore, Singapore
Share This Page